title: Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
abstract: Hypothesis Prior studies on patients with early B-cell lymphoid malignancies suggest that early intervention with curcumin may lead to delay in progressive disease and prolonged survival. These patients are characterized by increased susceptibility to infections. Rice bran arabinoxylan (Ribraxx) has been shown to have immunostimulatory, anti-inflammatory, and proapoptotic effects. We postulated that addition of Ribraxx to curcumin therapy may be of benefit. Study design Monoclonal gammopathy of undetermined significance (MGUS)/smoldering multiple myeloma (SMM) or stage 0/1 chronic lymphocytic leukemia (CLL) patients who had been on oral curcumin therapy for a period of 6 months or more were administered both curcumin (as Curcuforte) and Ribraxx. Methods Ten MGUS/SMM patients and 10 patients with stage 0/1 CLL were administered 6 g of curcumin and 2 g Ribraxx daily. Blood samples were collected at baseline and at 2-month intervals for a period of 6 months, and various markers were monitored. MGUS/SMM patients included full blood count (FBC); paraprotein; free light chains/ratio; C-reactive protein (CRP)and erythrocyte sedimentation rate (ESR); B2 microglobulin and immunological markers. Markers monitored for stage 0/1 CLL were FBC, CRP and ESR, and immunological markers. Results Of 10 MGUS/SMM patients,5 (50%) were neutropenic at baseline, and the Curcuforte/Ribraxx combination therapy showed an increased neutrophil count, varying between 10% and 90% among 8 of the 10 (80%) MGUS/SMM patients. An additional benefit of the combination therapy was the potent effect in reducing the raised ESR in 4 (44%) of the MGUS/SMM patients. Conclusion Addition of Ribraxx to curcumin therapy may be of benefit to patients with early-stage B-cell lymphoid malignancies.
authors.affiliation: St George Hospital, Sydney, Australia terry.golombick@sesiahs.health.nsw.gov.au.
authors.forename: Terry
authors.initials: T
authors.lastname: Golombick
authors.affiliation: St George Hospital, Sydney, Australia.
authors.forename: Terrence H
authors.initials: TH
authors.lastname: Diamond
authors.affiliation: University of Wollongong, NSW, Australia.
authors.forename: Arumugam
authors.initials: A
authors.lastname: Manoharan
authors.affiliation: University of Wollongong, NSW, Australia.
authors.forename: Rajeev
authors.initials: R
authors.lastname: Ramakrishna
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism; D003474:Curcumin / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009194:Myeloma Proteins / Q000378:metabolism; D012275:Oryza / Q000737:chemistry*; D014990:Xylans / Q000627:therapeutic use*
chemical_list: D014408:Biomarkers, Tumor; D009194:Myeloma Proteins; D014990:Xylans; C085016:multiple myeloma M-proteins; D002097:C-Reactive Protein; C085118:arabinoxylan; D003474:Curcumin
keywords: curcumin; early stage B-cell lymphoid malignancies; monoclonal gammopathy of undetermined significance (MGUS); rice bran arabinoxylan; smoldering myeloma (SMM); stage 0/1 chronic lymphocytic leukemia (CLL)